JAZZ Jazz Pharmaceuticals plc

NEUTRAL Impact: 3/10 Insider Cluster (3 insiders)
Horizon days Filed Jun 3, 2026 Processed 11d 11h ago
Insider cluster: 3 insiders, $3.3M total
Latest settled — T+1d ⚠ clustered
JAZZ ▼ -0.62% at T+1d
NEUTRAL call ✗ call lost -0.62% · α vs SPY +1.98% · entry $240.06 → $238.57
Next anchor: T+5d due 5d ago
Last close $230.56 (close Jun 12) · -3.96% from $240.06 entry
Entry anchored
Jun 3, 2026
via day open
T+1d
-0.62%
call -0.62% · α +1.98%
$238.57
settled 11d ago
T+5d
call — · α —
due 5d ago
T+20d
call — · α —
in 17d
T+60d
call — · α —
in 2mo

Price Chart

Loading chart...

Executive Summary

Three Jazz Pharmaceuticals insiders sold a total of $3.32M in open-market transactions over a 7-day window, including the Chief Commercial Officer and a Director. The sales are modest relative to the $14.2B market cap (~0.02%) and are partially offset by derivative exercises at lower strike prices, suggesting routine portfolio rebalancing rather than a bearish signal.

Key Financial Metrics

Direction
selling
Total Value
$3.3M
Insiders
3

Actionable Insight

The cluster is routine in size and composition — no material signal for traders. The derivative-exercise-linked sales suggest tax/vesting mechanics, not informed selling. Monitor the next 8-K or earnings release for any fundamental changes, but this filing alone does not warrant a position adjustment.

Key Facts

  • Total insider sales: $3.32M across 3 insiders (Director, EVP Chief Commercial Officer, EVP Chief Legal Officer)
  • Sales represent ~0.02% of Jazz's $14.2B market cap — well below the 0.1% materiality threshold
  • Two of the three sales (Pearce and Mulligan) were paired with derivative exercises at $109.45 and $138.08, indicating tax-covering or cashless exercise patterns
  • No insider purchases were reported in the cluster window
  • Prior 30-day insider activity: 5 sells totaling $4.5M, consistent with ongoing routine selling

Financial Impact

Total insider sales of $3.32M represent 0.02% of market cap — immaterial

insider ownershipfloat

Risk Factors

  • Insider selling could accelerate if management sees headwinds from Xywav/Xyrem patent cliffs or pipeline delays
  • Historical calibration shows JAZZ insider cluster reports have low predictive power (33% win rate at T+20)

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
92% bullish (25 analysts)

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-JAZZ-1780521015525
14 reports for JAZZ
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for JAZZ — sortable, filterable
Type Now
Jun 8, 2026
6d ago
DEFA14A
NEUTRAL ★ 3/10
$231.98 awaiting T+1awaiting T+1$230.56 (−0.61%)
Jun 3, 2026
11d ago
Insider Cluster
BEARISH ★ 5/10
$239.17 $238.57▲ +0.25%▼ −2.32%$230.56 (+3.60%)
Jun 3, 2026
11d ago
Insider Cluster
NEUTRAL ★ 3/10
$240.06 $238.57▼ −0.62%▲ +1.98%$230.56 (−3.96%)
Jun 1, 2026
13d ago
144
NEUTRAL ★ 3/10
$226.12 $230.93▲ +2.13%▲ +2.85%$230.56 (+1.96%)
May 29, 2026
16d ago
8-K
NEUTRAL ★ 2/10
$231.19 $226.12▼ −2.19%▼ −2.34%$230.56 (−0.27%)
May 1, 2026
6w ago
144
NEUTRAL ★ 2/10
$202.51 $207.89▲ +2.66%▲ +3.00%$230.56 (+13.85%)
Apr 24, 2026
7w ago
10-K/A
NEUTRAL ★ 4/10
$200.31 $203.07▲ +1.38%▲ +1.86%$230.56 (+15.10%)
Apr 1, 2026
10w ago
144
NEUTRAL ★ 3/10
$186.73 $185.83▼ −0.48%▼ −0.96%$230.56 (+23.47%)
Feb 27, 2026
15w ago
Insider Cluster
NEUTRAL ★ 3/10
$189.00 $190.30▲ +0.69%▲ +0.63%$230.56 (+21.99%)
Feb 27, 2026
15w ago
Insider Cluster
NEUTRAL ★ 3/10
$189.00 $190.30▲ +0.69%▲ +0.63%$230.56 (+21.99%)
Showing 10 of 14

US Market Status

Market Closed — Opens in 4h 39m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access